AbbVie — Upadacitinib (RINVOQ®) ✅ Active

• Phase 3 success (October 2025): Two replicate trials met co-primary endpoints
• T-VASI50: 19.4% (Study 1), 21.5% (Study 2)
• Full data & regulatory filings expected 2026

Incyte — Opzelura (ruxolitinib cream) ✅ Active

• Q4 2024: $162M (+48% YoY); Full year: $508M (+50%)
• 2025 guidance: $630-670M
• Ex-U.S. growth: France, Spain, Italy, Canada

Vyne Therapeutics — VYN201 ✗ Discontinued

• Phase 2b missed primary endpoint (July 2025)
• Program discontinued; seeking development partner

🇮🇱🇺🇸 Teva — TEV-53408 ✅ Active

• Phase 1b vitiligo: Ongoing, results expected 2026
• $500M from Royalty Pharma (January 2026)
• $75M for Phase 2b vitiligo (target start 2026)

🇺🇸 Amgen — AMG 714 ? Pending Results

• Phase 2 REVEAL trial completed May 2025
• 60 patients, NIAID-sponsored
• No published results as of January 2026

🇺🇸 Forte Biosciences — FB-102 ✅ Active

• Phase 1b vitiligo: Underway
• Topline results expected 1H 2026

AbbVie 🇺🇸 ✅ 

Upadacitinib (RINVOQ®), a selective JAK1 inhibitor, is in late-stage development for nonsegmental vitiligo. Two replicate Phase 3 trials in adults/adolescents (15 mg QD) met both co-primary endpoints at Week 48—T-VASI50 and F-VASI75—with a safety profile consistent with prior indications. Full results due 2026.

Ache Laboratorios Farmaceuticos 🇧🇷 ? 

ACH24: Set aside $100M for vitiligo in 2016; faced significant setbacks when Brazil's ANVISA requested Phase 3 cancellation, requiring a Phase 1 restart. Following setbacks, Aché partnered with Sun Pharma Global FZE to develop AS012 in the early 2020s.

❓ Aclaris Therapeutics

ATI-50002 (Topical JAK1/JAK3 inhibitor): Phase 2 completed 2020; no advancement since. ATI-1777 (next-gen soft JAK1/3) Phase 2b positive in AD (Jan 2024); vitiligo expansion mentioned but no trials initiated as of Jan 2026.

Ahammune Biosciences 🇮🇳 ✅ 

AB1001 (Topical small molecule, T-cell activation inhibitor): Completed Phase I in January 2023. Phase 2 IND granted May 2025. $5M funding raised Sept 2024. Non-steroidal, non-immunosuppressive, disease-modifying therapy.

🇪🇸 Almirall ? Early Stage

Wnt pathway-targeting therapy (partnership with Inserm Transfert, May 2022): Led by Prof. Thierry Passeron; aims to deliver novel class for vitiligo. Status unclear; no trial updates.

🇺🇸 Alys Pharmaceuticals ? Pending

Emerged 2024 with $100M from Medicxi; pooled 6 biotech startups. Focus: inflammatory/autoimmune, dermatology for cancer patients, rare skin conditions. Goal: 7-10 clinical POC readouts next 3 years. Vitiligo interest unconfirmed.

🇺🇸 Amgen ? Pending Results

AMG 714 (Ordesekimab): Designed to block IL-15, targeting tissue resident memory T cells. Phase 2 trial completed May 2025; no published results as of October 2025.

❌ AnaptysBio ✗ Discontinued

Rosnilimab (Anti-PD-1 agonist): Moved to Phase 2b for RA (Q3 2023); vitiligo no longer acknowledged on website.

❌ Applied Biology / Safety Shot ✗ OTC Only

Photocil (NB-UVB filter cream): FDA-registered OTC for vitiligo, psoriasis, AD. Selectively transmits 311-313nm. Acquired by Jupiter Wellness (now Safety Shot) July 2022; rebranded PhotoFirst; CDSCO approval India Nov 2022. Not FDA-approved prescription therapy; positioned as adjunct.

🇺🇸 Arcutis Biotherapeutics ? Preclinical

ARQ-252 (SHR0302, JAK1 inhibitor licensed from Jiangsu Hengrui): Phase IIa terminated June 2021; back at preclinical stage for chronic hand eczema and vitiligo. Roflumilast 0.3% foam (PDE4 inhibitor): Phase 2 vitiligo & hidradenitis suppurativa studies ongoing.

❓ Arrien Pharmaceuticals ? IND-enabling

ARN-4079 (Oral JAK3/ITK inhibitor, Cys909 targeting): IND-enabling studies; seeking partners for Phase 1. Vitiligo among lead indications. $2M + undisclosed funding; no trial initiated.

🇬🇧 AstraZeneca ✅ Active

Anifrolumab (Saphnelo) — Phase 2 (NCT05917561) combining anifrolumab with NB-UVB for vitiligo. Approved for SLE 2021; exploring IFN-I pathway modulation.

🇺🇸 Avita Medical ✅ Active

RECELL® System: FDA-approved device (2023) for vitiligo. Creates autologous skin cell suspension in <30 min; apply to laser-prepared stable lesions. 36% achieved ≥80% repigmentation at 6 months in pivotal trials.

❌ AXIM Biotechnologies ✗ Inactive

AX-1602 (CBD/CBG topical): Initially patented for vitiligo; never advanced beyond single POC study. Program inactive; company focused on psoriasis, eczema, ophthalmology, neurology.

🇮🇱 Biolojic Design / Teva ? Early Stage

BD9 (Dual IL-13/TSLP antibody, AI-driven multibody platform): IND-enabling studies for AD and asthma. Vitiligo potential noted but no active trial.

🇺🇸 Bioniz Therapeutics / Almirall ? Phase 2-Ready

BNZ-1 (Multi-cytokine inhibitor: IL-2, IL-9, IL-15): Phase 2-ready; demonstrated safety in CTCL Phase 1/2. Vitiligo listed as lead indication but no active trials as of Jan 2026.

🇩🇪 Boehringer Ingelheim ? Early Interest

No proprietary trials for vitiligo. Early-stage interest; strong external partnering strategy. Focus on advocacy, pediatric support, foundational research. Future involvement likely via in-licensing.

❌ Boston Pharmaceuticals ✗ No Updates

BOS-475 (formerly GSK3183475): In-licensed from GSK after R&D restructuring. Not in active pipeline; no updates post-acquisition.

🇺🇸 Bristol Myers Squibb ✅ Active

Deucravacitinib (Sotyktu) (Oral TYK2 inhibitor): Phase 2/3 vitiligo + NB-UVB (NCT06327321). Approved for psoriasis 2022; PsA sNDA PDUFA March 6, 2026. Direct-to-patient platform launching Jan 2026. Vitiligo exploratory.

🇺🇸 CAGE Bio ✓ Active

CGB-600 (DNA aptamer targeting IFN-γ): Phase 2 initiated Oct 2025; 36 patients, facial NSV; topline Q3 2026. Licensed from TAGCyx (Japan); ionic liquid delivery. First DNA aptamer for vitiligo.

❓ Castle Creek Pharma ? Uncertain

CCP-070 (Peptide analogs): Preclinical program from Univ. of Cincinnati; aims to stimulate melanogenesis. No toxicology studies or timelines disclosed; focus shifted to gene therapies. Likely suspended.

🇨🇳 China Medical System ✓ Active

Ruxolitinib Phosphate Cream: Licensed from Incyte for mainland China, HK, Macau, Taiwan, SE Asia. NDA accepted by NMPA for vitiligo. Already approved HK/Macau for NSV with facial involvement (age 12+). Phase 3 AD trial positive (Jan 2026). Manufacturing scale-up completed locally.

Povorcitinib (Oral JAK1 inhibitor, licensed from Incyte): Breakthrough Therapy designation NMPA Dec 2025. Phase 3 global trial met primary endpoint March 2025. China Phase 3 initiated Aug 2025; NDA filed Sept 2024. HK/Macau approved via fast-track policy. If approved: first oral JAK for vitiligo in China.

🇨🇳 CSPC Ouyi Pharmaceutical ✓ Active

SYHX1901 (Oral TYK2 inhibitor): Phase 2 (NCT06511739) for vitiligo. Targets immune-mediated diseases; CSPC entry into immunodermatology market.

🇦🇺 Clinuvel ✓ Active

SCENESSE® (Afamelanotide 16mg) (α-MSH analog, SC implant): Phase 3 CUV105 enrollment completed May 2025 (200+ patients, 37 sites). Fitzpatrick III-VI focus; afamelanotide + NB-UVB vs NB-UVB alone. Full results 2H 2026. Early case reports: rapid repigmentation (as early as 4 weeks), though diffuse hyperpigmentation in lighter skin types is concern.

❌ Dermavant / Roivant / Organon ✗ Discontinued

Cerdulatinib (DMVT-504) (JAK/SYK inhibitor): Deprioritized July 2022 before entering trials. Absent from pipeline Oct 2025; R&D redirected to VTAMA® (tapinarof for psoriasis). Acquired by Organon 2024; no active vitiligo R&D.

🇨🇳 Dermavon (CMS Spin-off) ✓ Active

Povorcitinib (Oral JAK1 inhibitor, licensed from Incyte): Breakthrough Therapy designation NMPA Dec 2025. Phase 3 global trial met primary endpoint March 2025. China Phase 3 initiated Aug 2025; NDA filed Sept 2024. HK/Macau approved via fast-track policy. If approved: first oral JAK for vitiligo in China. Also co-develops MG-K10 (anti-IL-4Rα antibody) Phase 3 AD; potential extension to vitiligo.

🇮🇳 DRDO / AIMIL Pharma

Lukoskin (Ayurvedic polyherbal: ointment + oral liquid): Enhances photosensitivity, melanogenesis, immune modulation. Widely available in India; affordable, safe, culturally accepted. Clinical efficacy modest, comparable to other adjunctive herbal therapies.

🇨🇦 Edesa Biotech ✓ Active

EB06 (Anti-CXCL10 mAb): First-in-class blocking CXCL10 chemokine to disrupt T-cell recruitment. Phase 2 planned mid-2026 (~160 patients, moderate-to-severe NSV). CTA granted Health Canada (NCT05724952 active, not recruiting); IND in progress U.S. Dosing: IV q2 weeks x 24 weeks, then 12-week follow-up. Primary: F-VASI50 at Week 24. $15M funding to advance through fiscal 2026. Preclinical: reversed vitiligo in mouse models.

🇫🇷/🇺🇸 Eligo Bioscience ? Preclinical

CRISPR-guided microbiome therapies: Patents for Cutibacterium acnes engineering. Lead EB005: acne (preclinical/early patient data). Vitiligo in patent scope but no active clinical program as of 2025.

🇺🇸 Forte Biosciences ✓ Active

FB-102 (Anti-CD122 mAb): Phase 1b vitiligo underway; topline results 1H 2026. Targets IL-2/IL-15 receptor shared subunit (CD122). Phase 1b celiac disease positive data (June 2025): p=0.0099 on composite endpoint. Mechanism: Suppresses pathogenic CD8+ memory T cells and NK cells while sparing Tregs.

🇨🇳 Huahai Institute of Vitiligo Research

Founded 1994; leading center integrating TCM with modern biomedicine. Developed several patented oral, topical, injectable therapies. No internationally recognized clinical trials or peer-reviewed efficacy data as of 2025.

🇨🇭 Idorsia Pharmaceuticals ✓ Active

ACT-777991 (Oral CXCR3 antagonist): First-in-class dual targeting CD8+ CXCR3+ T cells + melanocytes. Proof-of-concept Phase 2 in preparation; trial initiation expected 2026. Aims to be first targeted systemic for immuno-dermatology. Preclinical: synergistic remission with anti-CD3 in T1D (82% remission vs 38% for anti-CD3 alone).

🇦🇺 Incannex Healthcare ? Clinical Stage

ReneCann (APIRx-1601) (CBD/CBG topical): Cannabinoid-based cream for vitiligo, psoriasis, and atopic dermatitis. Proof-of-concept study in the Netherlands showed ~10% disease score reduction and diffuse repigmentation, though relapse occurred. Manufacturing underway for confirmatory trials; regulatory filings in preparation.

🇨🇳 InnoCare Pharma ✓ Active

Soficitinib (ICP-332) (TYK2/JAK1 inhibitor): Vitiligo Phase 2/3 initiated May 2025 (China), enrollment underway. AD Phase 3 registrational trial accelerating; Phase 2 data (AAD 2025) outstanding efficacy. Prurigo nodularis Phase 2 global initiated Nov 2025. CSU Phase 2/3 IND approved Dec 2025. China-focused, global expansion planned.

🇨🇳 Issar Pharma / Zydus ✓ Active

Melgain (Decapeptide Topical): First peptide-based topical for vitiligo, stimulating melanocyte migration and repigmentation. Marketed in India by Zydus/Liva Healthcare; real-world data support limited use in adults and children. Zydus holds rights for potential international expansion.

🇨🇳 Jiangsu HengRui Medicine ✓ Active

SHR0302Base (Topical JAK1 inhibitor): Global Phase 2 trials for vitiligo. Oral counterpart in Phase 3 China for RA and AS. Arcutis licensed topical formulation 2018 (now ARQ-252); terminated Phase IIa mid-2021, re-evaluating at preclinical.

🇺🇸 JN Biosciences ? Early Stage

HuABC2 (Anti-CD122 mAb): Humanized mAb, available for out-licensing. Mouse vitiligo model: Reversed established disease; short-term treatment provided durable repigmentation. Non-human primate studies: Well-tolerated; CD122 occupancy >14 days. Seeking partners for human trials.

🇰🇼 🇳🇱 Kuwait University / Rebel-Nature

VT Treatment (Plant-based, two-phase topical): Natural photosensitizers + antioxidants/immunomodulators. Local trials Kuwait 2018-2019: safety & efficacy in NSV, Fitzpatrick III+. Positioned as safer alternative to PUVA/NB-UVB. Registered EU, UK, Saudi Arabia. Large-scale production faces raw material challenges.

🇩🇰 LEO Pharma

Tacrolimus (Protopic): Not pursuing proprietary vitiligo assets; Protopic widely used off-label. 65% improvement after 24 weeks (BID); ~40% relapse at 48 weeks. R&D focus: AD, psoriasis, inflammatory dermatoses.

🇬🇧 Life Science Investments

VitiLSi™ (Botanical gel): R&D facilities Guayaquil, Ecuador. Cosmeceutical using Coleus forskohlii and Cassia alata extracts. Controlled studies: up to 41% repigmentation after 8 weeks, especially with phototherapy. Positioned for acrofacial vitiligo. Long-term efficacy unproven.

❌ Merck ✗ Discontinued

MK-6194 (IL-2 mutein from Pandion): Acquired $1.85B in 2021; discontinued July 2025 after Phase 2 failure in lupus & vitiligo. Part of $3B cost-cutting initiative.

🇺🇸 Novartis ? Inconclusive

Ex-U.S. commercialization rights to ruxolitinib (Jakavi) for heme/onc; Incyte retains Opzelura globally. Secukinumab (Cosentyx) pilot trial (NCT05676333) in vitiligo: inconclusive results. IL-17A pathway challenged as treatment target; research suggests Th17.1/Th1 balance more critical. Broad immunology pipeline signals ongoing interest in immune-driven dermatology.

🇮🇱 Novoxel

Tixel Device (Thermomechanical ablation): Boosts topical drug absorption (betamethasone, tacrolimus). 2022 study: 6-8ms exposure, 400-600μm protrusion; faster repigmentation in stable/resistant vitiligo with mild reactions. No updates since 2022.

🇺🇸 Nektar Therapeutics ✓ Active

NKTR-0165 (TNFR2 agonist): First-in-class bivalent antibody activating Tregs via TNFR2. Aims to restore immune tolerance without broad suppression. Preclinical: enhanced Treg stability, reduced inflammation. Indications: ulcerative colitis, vitiligo. IND-enabling studies; first-in-human trials expected 2025 in collaboration with Biolojic Design.

🇺🇸 OM1 ✓ Active

Phenome AI Platform (Boston): Applies AI to millions of derm records, including AAD's DataDerm registry. Builds vitiligo-specific datasets & predictive models. Provides real-world evidence for regulatory filings, clinical decisions, outcomes research. De-risks vitiligo clinical trials via precise cohort identification.

❓ Ornovi ? No Updates

OR-101 (Oral covalent JAK3/ITK inhibitor, Cys909 targeting): Preclinical 2023: efficacy in vitiligo & alopecia areata. Designed for greater safety/selectivity than first-gen JAKs. No clinical updates >1 year; status unclear.

❓ Palatin Technologies ? No Vitiligo Trials

MC1R Agonist Peptides: Patent portfolio since 2013 for MC-1 peptides in vitiligo & EPP. Lead PL-8177 in early clinical for ulcerative colitis (anti-inflammatory). No active vitiligo trials as of 2025.

❌ Pandion Therapeutics / Merck ✗ Discontinued

MK-6194 (IL-2 mutein): See Merck above (acquired $1.85B 2021, discontinued July 2025)

🇫🇷 Pierre Fabre

Epidemiology, off-label use, repigmentation maintenance: RV5098A trial (topical for maintaining pigmentation in repigmented facial lesions) completed June 2024; results not posted. Produces 5% 5-fluorouracil used off-label India (limited tolerability). No new vitiligo drug programs; focus on epidemiology, existing derm products.

🇺🇸 Pfizer ✓ Active

Ritlecitinib (LITFULO™) (Oral JAK3/TEC inhibitor): Phase 3 TRANQUILLO program (~2,050 patients, 17 countries). Primary completion March 2026; extension trial (NCT07152626) initiated. Already approved for severe alopecia areata (U.S., Japan). Phase 2b: first oral JAK to show stabilization of active lesions AND repigmentation of stable ones.

Crisaborole (Topical PDE4 inhibitor): Phase 2 vitiligo as monotherapy & with NB-UVB wrapped March 2024; no results posted.

🇨🇳 Reistone Biopharma ✓ Active

Advancing small-molecule & biologic therapies for vitiligo; targeting JAK & BET proteins. Late-stage vitiligo data not yet public. JAK inhibitors in alopecia & other skin diseases may extend into vitiligo.

❌ Rheos Medicines ✗ Discontinued

Immunometabolism Platform (T-cell metabolism modulators): Raised $60M (Third Rock); $800M Roche collaboration 2019. No programs to clinic; company shut down 2023 amid funding challenges. All vitiligo development discontinued.

❌ Rhythm Pharmaceuticals ✗ No Vitiligo Development

Setmelanotide (MC4R agonist): Approved for rare monogenic obesity. Causes consistent skin darkening 56–78% patients via off-target MC1R activation. Pigmentation milder than afamelanotide but frequent. No current vitiligo development; repurposing theoretical.

🇺🇸 Safety Shot

Photocil — See Applied Biology above

🇪🇸 Sesderma

VITISES (Cosmeceutical line): Nanotechnology-based gels, lotions, supplements; liposome-encapsulated phenylalanine, khellin. Popular Middle East, Asia, Latin America; not actively marketed EU/USA due to regulatory/commercial hurdles. Cosmeceuticals, not approved medical treatments; evidence limited to small studies.

🇨🇦 Skinopathy ✓ Active

AI Dermatology Platform: GetSkinHelp app for vitiligo; mobile image analysis, remote consultations. Pilots with OBIO, peopleCare. Health Canada licensing confirms regulatory engagement. Large-scale peer-reviewed validation pending.

🇺🇸 Strata Skin Sciences ✓ Active

XTRAC® excimer laser (308nm UVB): FDA-cleared for vitiligo & psoriasis. Proven efficacy in stable cases, paired with topicals. TheraClear®X (acne system) added, expanding in-office dermatology. 400+ peer-reviewed studies.

🇮🇳 Sun Pharmaceuticals ✓ Active

Ruxolitinib 1.5% cream: Phase 3 CDSCO approval Aug 2025 (Protocol ICR/24/008). Comparator: Decapeptide (Melgain); standardized UVB/sunlight exposure. Patients 12+ with NSV. Also Phase 3 for AD (separate trial, Dec 2025 update).

🇺🇸 Temprian Therapeutics ✓ Preclinical

TT-01 (DNA-based therapy, modified HSP70i): Four needle-free DNA injections for whole-body repigmentation. Pre-IND meeting completed; $4M NIH grant. Aims for durable effect, including distant lesions. Late preclinical; human trials anticipated but not yet initiated. No updates since 2020.

🇮🇱 Teva Pharmaceuticals ✓ Active

TEV-53408 (Anti-IL-15 mAb): Phase 1b vitiligo (NCT06625177): Ongoing, results expected 2026. Major funding: $500M from Royalty Pharma (January 2026)—$75M for Phase 2b vitiligo (target start 2026), up to $425M additional. Mechanism: Subcutaneous mAb blocking IL-15 activity, reducing TRM cell survival. Fast Track designation (FDA, May 2025) for celiac disease; Phase 2a underway. Rationale: Mouse models show 8-week IL-15 blockade depletes autoreactive TRM cells, achieving sustained repigmentation even after treatment cessation.

🇺🇸 TeVido BioDevices ✓ Early Clinical

TruPigment (Autologous cell therapy): Office-based kit for melanocyte harvest & reapplication in stable, localized vitiligo. Designed for accessibility, lower cost. Not FDA-cleared as medical device; registered as Tissue Establishment. $1.4M private funding; early clinical use, limited U.S. availability as training & reimbursement expand.

🇮🇳 Uniza Healthcare

Vitellus (Palmitoyl tetrapeptide + pro-melanogenic/antioxidant supplements): Partnership with Lucas Meyer Cosmetics (Canada) & Amvigor Organics (India). Peptide-based lotions available India since 2004; efficacy often short of marketing claims.

❌ Vallaurix (Clinuvel Subsidiary) ✗ Suspended

VLRX001 (Topical melanocortin analogue): Announced 2020 as complement to systemic afamelanotide; maintenance therapy for vitiligo Fitzpatrick IV–VI. Early in vitro promise. No public updates, trials, or regulatory activity since. Likely suspended or deprioritized.

❌ Vilacto Bio ✗ Uncertain Prospects

Lactoactive Nanoparticle System: Promoted as nanotech platform from bovine colostrum for immunomodulation & skin regeneration. No evidence of advanced clinical/regulatory progress. Severe financial strain; vitiligo prospects highly uncertain.

❌ Villaris Therapeutics / Incyte ✗ On Hold

Auremolimab (VM6/INCA034460): Incyte acquired Villaris 2022 ($70M upfront). IND cleared and first patient dosed Phase 1 in 2023. Development paused October 2025 (pipeline prioritization). No longer in Oct 2025 portfolio; scientific rationale remains valid.

🇺🇸 Vyne Therapeutics ✗ Discontinued

VYN201 (repibresib) (BET Inhibitor): Topical "soft" pan-BET inhibitor for nonsegmental vitiligo. Phase 1b showed ~39% mean F-VASI improvement at highest dose with good tolerability; Phase 2b topline readout (July 2025) reported missed primary endpoint with high vehicle effect (placebo -25.6% vs active -43.6%) and high dropout (36.6% active vs 10.6% vehicle). Program discontinued; seeking development partner.

🇨🇳 Xinjiang Biomedicine Innovation Center

With Uzbek partners: reports early success adapting traditional Uygur medicine for vitiligo; herbal formulas + modern validation. Pilot studies suggest repigmentation benefits. No peer-reviewed data or regulatory filings; progress preliminary, regionally reported.

🇺🇸 Zerigo Health ✓ Active

Connected NB-UVB Phototherapy System: FDA-cleared handheld for at-home treatment (vitiligo, psoriasis, eczema, all skin types). Dosing controlled via physician-prescribed mobile app. Integration allows treatment schedules, progress photos, data sharing with care teams.